earn updat provid
liver safeti eye remain easl
clarif liver safeti necessari reassur addit data
liver safeti suggest dose-depend liver toxic signal
oca nash patient analyz date met first
requir hy law peak alt uln bilirubin uln
placebo oca none patient
seriou advers event sae liver-bas sae
follow-up call manag provid addit color spoke
team confer call today learn averag
time therapi entir trial approxim month
cohort patient therapi year prevent
safeti data skew patient recent random
provid addit reassur skeptic investor also
learn gener overal liver enzym level decreas treatment
continu anticip specif liver enzym weight loss
correl non-invas diagnost and/or biomark
posit oca respons easl april
price remain miss piec nash stori intercept
provid detail commerci plan nash launch
continu keep price plan close vest compani maintain
strong posit negoti payor continu
expect intercept price oca nash current price
model adjust increas oca market share patient
lower estim patient receiv therapi respons failur
gilead trial also reduc pbc estim slightli
line guidanc lower ep
risk thesi includ clinic regulatori commerci headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc american biopharmaceut
compani focus develop novel synthet bile acid
analog treat chronic liver diseas pbc nafld nash
cirrhosi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
scenario intercept repres
credit compani on-going phase trial nash
increas growth rate ocaliva pbc nash largest
growth driver compani
grey scenario intercept repres
credit compani on-going phase trial nash use
po would surpris trial outright
failur believ scenario reflect worst-cas
valuat compani
 close
compani mention price
